Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Shares Outstanding (2016 - 2024)

Abvc Biopharma (ABVC) has disclosed Shares Outstanding for 9 consecutive years, with -$731031.0 as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Shares Outstanding fell 2554.92% year-over-year to -$731031.0, compared with a TTM value of -$731031.0 through Sep 2024, down 2554.92%, and an annual FY2023 reading of $7.9 million, up 141.66% over the prior year.
  • Shares Outstanding was -$731031.0 for Q3 2024 at Abvc Biopharma, down from $12.1 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $32.6 million in Q3 2022 and bottomed at -$731031.0 in Q3 2024.
  • Average Shares Outstanding over 5 years is $12.7 million, with a median of $10.7 million recorded in 2024.
  • Peak annual rise in Shares Outstanding hit 43869.1% in 2024, while the deepest fall reached 2554.92% in 2024.
  • Year by year, Shares Outstanding stood at $24.4 million in 2020, then plummeted by 100.11% to -$27535.0 in 2021, then surged by 12034.59% to $3.3 million in 2022, then soared by 141.63% to $7.9 million in 2023, then plummeted by 109.21% to -$731031.0 in 2024.
  • Business Quant data shows Shares Outstanding for ABVC at -$731031.0 in Q3 2024, $12.1 million in Q2 2024, and $10.7 million in Q1 2024.